FDA's Letter to Heron Therapeutics (HRTX) Over Sustol Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
FDA Approval of Heron Therapeutics' (HRTX) Sustol Removes Major Overhang - Analyst
August 10, 2016 11:14 AM EDTLeerink affirms Heron Therapeutics (Nasdaq: HRTX) at Outperform with a price target of $33 following FDA approval of Sustol for treatment of chemo induced nausea and vomiting.
Analyst Jason Gerberry commented today: We are still reviewing the package insert, but Sustol... More
Pre-Open Stock Movers 08/10: (CLNE) (OCN) (HRTX) (YELP) Higher; (GEVO) (SPWR) (MYGN) (PRGO) Lower (more...)
August 10, 2016 9:28 AM EDTToday's Pre-Open Stock Movers
Gevo (NASDAQ: GEVO) 30% LOWER; reported Q2 EPS of ($0.15), versus ($0.66) reported last year. Revenue for the quarter came in at $8.11 million, versus $8.9 million reported last year.
SunPower (NASDAQ: SPWR) 30% LOWER; reported Q2 EPS of ($0.22), $0.02 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $420.5 million versus the consensus estimate of $345.08 million. GUIDANCE:... More
Heron Therapeutics (HRTX) Reports FDA Approval of SUSTOL
August 10, 2016 8:33 AM EDTHeron Therapeutics, Inc. (Nasdaq: HRTX) announced that the U.S. Food and Drug Administration (FDA) has approved SUSTOL® (granisetron) extended-release injection. SUSTOL is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.
SUSTOL is an extended-release, injectable 5-HT3 receptor antagonist that utilizes Herons Biochronomer® polymer-based drug delivery technology to maintain therapeutic levels of granisetron for 5 days, covering both the acute and... More
Heron Therapeutics (HRTX) Halted, News Pending
August 10, 2016 8:25 AM EDTHeron Therapeutics (NASDAQ: HRTX) Halted, News Pending
... More